ECIO 2012 - THE SCIENTIFIC GEMS
SCIENCE LEAPS FORWARD AT ECIO 2012
Vienna, Austria, 04 May 2012
As can be expected from Europe’s top interventional oncology forum, this year’s European Conference on Interventional Oncology (ECIO 2012) had many scientific gems to offer.
The congress opened with a look at cutting-edge research, in Image-guided tumour ablation: technological advances. New ablation methods such as focused ultrasound, microwave ablation and irreversible electroporation were discussed, and the session also examined whether in light of these new data, the “gold-standard” therapy, radiofrequency ablation, is still a viable and effective treatment option.
A CURATIVE ROLE IN HCC
The second day of the congress opened with what was to prove the most popular session of the congress: Curative treatments for HCC. Data to support the use of IR in managing HCC has long existed, but exciting new data is being forwarded that suggests a curative role.
POLITICS AND PARTNERSHIP
This year’s honorary lecture, Treating cancer in the transparent patient, was delivered by Prof. Andreas Adam. The lecture dealt largely with the clinical and political aspects of interventional oncology, and Prof. Adam argued that in order to deliver robust and effective treatment safely, interventional oncology (and interventional radiology generally) must remain anchored within the radiology department, as well as developing their natural partnership with radiation oncologists further.
In the true sense of partnership, ECIO was proud to give the stage to renowned radiation oncologist and guest speaker, Dr. Lizbeth Kenny. Dr. Kenny presented on the importance of interdisciplinary collaboration for the benefit of the cancer patient, during the session debut Training in Interventional Oncology: beyond technology. The culminating expert debate dealt with the question, “is it time to create a curriculum in interventional oncology?” – a topic and format likely to feature in the future.
Advances were further explored in Image-guided therapies: new clinical applications, which examined expanding the use established interventional therapies for liver, lung and kidney to treat further organ groups, such as the pancreas, adrenal glands and prostate.
Drug delivery in interventional oncology gave a fascinating introduction to the most dynamic area of oncology – local delivery of targeted drugs. IR plays a central role in accurately deploying the gene-therapies, thermally activated liposomes and modified viruses that herald the future of cancer treatment.
These inspiring lectures and others will soon be available for viewing on www.esir.org.